•  
  •  
  •  
  •  

2025-09-28 19:54:07

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark

Keywords Selected:  INE049B01025

Stock Report

  • THE LANCET Regional Health publishes Pivotal Phase 3 Clinical Study on Miqnaf®
  • Leading U.K. Medical Journal publishes a Complex Case of Severe Pandrug Resistant Infection in U.S. Liver Transplant Patient Successfully Treated with Zaynich®
  • Wockhardt initiates strategic realignment of US Operations to focus on Innovative Portfolio
  • Paediatric US Cancer Patient with Recalcitrant Blood and Liver Infection Successfully Treated with Zaynich™
  • Zaynich™ enables US cancer patient undergo successful liver transplant and resume chemotherapy by eradicating dual extreme drug resistant Gram negative pathogens
  • Wockhardt files fast-acting Insulin Aspart injection with DCGI
  • Wockhardt's yet another novel antibiotic Miqnaf™ receives favourable recommendation from Subject Expert Committee of CDSCO for the Treatment of CABP
  • Dr. Habil Khorakiwala bestowed Lifetime Achievement Award by Integrated Health and Wellbeing Council in Dubai
  • Wockhardt's Investigational Drug, Zaynich™ cures complex case of meningitis caused by pan-drug resistant super-bug under compassionate use
  • Wockhardt wins prestigious Innovator Award from Government of India
  • Globally renowned US body CLSI awards high susceptibility breakpoints to Zaynich
  • Wockhardt announces successful completion of pivotal Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
  • Ind-Ra revises ratings of Wockhardt Ltd
  • Wockhardt promoters sell stake, reinvest proceeds in the company
  • Wockhardt Ltd closes Illinois manufacturing facility
  • Wockhardt announces successful initiation of Global Phase 3 Clinical Study of its novel antibiotic WCK 5222
  • Wockhardt Ltd allots 3,32,44,650 Equity Shares
  • Wockhardt and Serum Life Sciences UK announce collaboration for manufacturing multiple vaccines in UK
  • NIH, USA to conduct human Phase 1 trial of Wockhardt's novel once-a-day MDR Gram-negative antibiotic WCK 6777
  • Wockhardt Limited announces 3:10 rights issue at Rs. 225 per share
  • Wockhardt to consider rights issue terms and conditions on March 3, 2022
  • Wockhardt gets CDSCO nod for exporting up to 100 million doses of Sputnik Vaccines
  • Wockhardt Limited board approves rights issue to raise Rs. 1000 crore
  • Wockhardt Limited board to consider fund raising options on Jan 6, 2022

Latest Post

  • Umiya Mobile Limited Strengthens Market Presence with 36 New Stores Post IPO
  • Avantel Ltd to inaugurate new facility on Oct 2, 2025
  • Solarium Green Energy Ltd receives orders worth Rs. 18.77 crores
  • Capricorn Systems Global Solutions Ltd receives order for supply of broken rice
  • Anand Rayons Ltd receives approval for STAPII trademark


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024